P

    Phio Pharmaceuticals Corp (PHIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.09
    -0.04 (-3.54%)

    Market Cap: $13.13M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(24/34)
    Avg Surprise
    +3.03%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.37 - $-0.35
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.33+9.7%
    60d ago$-0.33+9.7%
    30d ago$-0.33+9.7%
    7d ago$-0.35+2.8%
    Current$-0.36
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.49
    Range$-0.52 - $-0.47
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.49---
    Sep 26EST
    		-$-0.36---
    Jun 26
    		$-0.36$-0.36+0.00%Beat+20.0%
    Mar 26
    		$-0.34$-0.23-47.83%Miss+17.1%
    Dec 25
    		$-0.15N/A+68.09%Beat+82.4%
    Sep 25
    		$-0.44$-0.44+0.00%Beat+71.4%
    Jun 25
    		$-0.45$-0.36-25.00%Miss+87.6%
    Mar 25
    		$-0.41$0.00N/ABeat+73.2%
    Dec 24
    		$-0.85$-1.23+30.89%Beat+0.0%
    Sep 24
    		$-1.54N/A+62.80%Beat+85.0%
    Jun 24
    		$-3.62$-4.59+21.13%Beat-145.5%
    Mar 24
    		$-1.53N/A+86.92%Beat+51.5%
    Dec 23
    		$-0.85$-1.30+34.62%Beat+96.1%
    Sep 23
    		$-10.26$-12.87+20.28%Beat+63.5%
    Jun 23
    		$-1.47$0.00N/ABeat+92.8%
    Mar 23
    		$-3.15$0.00N/ABeat+84.6%
    Dec 22
    		$-21.78$-29.16+25.31%Beat-572.2%
    Sep 22
    		$-28.08$38.88-172.22%Miss+7.1%
    Jun 22
    		$-20.52$-33.48+38.71%Beat+5.0%
    Mar 22
    		$-20.52$-32.40+36.67%Beat-6312.5%
    Dec 21
    		$-3.24$-3.84+15.63%Beat+92.7%
    Sep 21
    		$-30.24$-27.00-12.00%Miss+30.0%
    Jun 21
    		$-21.60$-28.08+23.08%Beat+41.2%
    Mar 21
    		$-0.32$0.00N/ABeat+75.9%
    Dec 20
    		$-44.28$-45.36+2.38%Beat+91.8%
    Sep 20
    		$-43.20$-40.50-6.67%Miss+90.9%
    Jun 20
    		$-36.72$-69.66+47.29%Beat+92.3%
    Mar 20
    		$-1.33$0.00N/ABeat+99.8%
    Dec 19
    		$-543.24$-475.20-14.32%Miss-723.1%
    Sep 19
    		$-475.20$-475.20+0.00%Beat+76.5%
    Jun 19
    		$-475.20$-475.20+0.00%Beat+82.6%
    Mar 19
    		$-594.00$-475.20-25.00%Miss-1106.6%
    Dec 18
    		$-66.00$-72.60+9.09%Beat+98.7%
    Sep 18
    		$-2019.60$-2643.30+23.60%Beat+69.1%
    Jun 18
    		$-2732.40$-3504.61+22.03%Beat+57.6%
    Mar 18
    		$-49.23N/AN/ABeat+99.3%
    Dec 17
    		$-4989.61$-5702.41+12.50%Beat-26.0%
    Sep 17
    		$-6534.01$-6534.01+0.00%Beat+67.6%
    Jun 17
    		$-6444.91$-6534.01+1.36%Beat-
    Mar 17
    		$-7128.01$-6534.01-9.09%Miss-
    Dec 16
    		$-3960.00$-1518.00-160.87%Miss-
    Sep 16
    		$-20196.03$-19008.03-6.25%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.84EV/EBITDA0.61x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-113.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.39xQuick Ratio8.39x
    Trading Statistics
    Beta0.79Avg Volume174.94K
    52-Week High$2.5752-Week Low$0.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.15
    SMA 20$1.11
    SMA 50$1.06
    SMA 200$1.13
    EMA 10$1.13
    EMA 20$1.11
    EMA 50$1.09
    EMA 200$1.23

    MACD

    Line: 0.02Signal: 0.03Hist: -0.00

    ADX

    ADX: 14.6+DI: 20.3-DI: 21.4

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down12.0
    PSAR$1.23

    Bollinger Bands

    Upper Band$1.22
    Lower Band$1.00
    %B Position1987%(Upper)
    Band Width0.41

    RSI (14-Day)

    Neutral
    48.4

    Momentum Oscillators

    Stoch %K40.5
    Stoch %D56.4
    Williams %R-71.4
    ROC (10d)2.8%
    Momentum0.03
    CCI (20d)-13.9
    MFI (14d)60.7

    Volatility Measures

    ATR (14d)$0.07(6.0%)
    StdDev (20d)0.06
    Hist Vol54.0%(High)

    Volume Flow

    VWAP$1.10
    OBV236.4M
    AD Line-453.1M
    CMF (20d)0.134

    Volume Metrics

    Avg Vol (20d)180.3K
    Vol Ratio1.3x
    VWMA (20d)$1.13

    Pivot Points

    R3$1.19
    R2$1.17
    R1$1.15
    Pivot Point$1.13
    S1$1.11
    S2$1.09
    S3$1.07

    Advanced Oscillators

    TSI12.21
    Ultimate Osc43.2
    KST106.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$70,000$0$0$0$6,000$0
    Cost of Revenue$0$0$1,000$0$0$0$35,000$0$0$0N/A$0
    Gross Profit$0$0$-1,000$0$0$0$35,000$0$0$0$6,000$0
    Operating Expenses$4.27M$4.17M$2.53M$2.50M$2.31M$1.87M$1.67M$1.59M$1.91M$2.21M$1.90M$2.78M
    R&D$3.08M$2.79M$1.48M$1.18M$1.07M$886,000$985,000$644,000$866,000$1.15M$1.01M$1.81M
    SG&A$1.19M$1.37M$1.06M$1.32M$1.24M$986,000$689,000$946,000$1.05M$1.06M$766,000$968,000
    Operating Income$-4,268,000$-4,167,000$-2,534,000$-2,505,000$-2,309,000$-1,872,000$-1,674,000$-1,590,000$-1,914,000$-2,209,000$-1,899,000$-2,776,000
    Interest Income$130,000$161,000$0$113,000$143,000$125,000$0$66,000$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$-53,000$2,000$4,000
    Income Before Tax$-4,138,000$-4,003,000$-2,393,000$-2,392,000$-2,166,000$-1,769,000$-1,626,000$-1,524,000$-1,846,000$-2,154,000$-1,901,000$-2,780,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,138,000$-4,003,000$-2,371,000$-2,392,000$-2,166,000$-1,769,000$-1,626,000$-1,524,000$-1,846,000$-2,154,000$-1,895,000$-2,780,000
    EBITDA$-4,267,000$-4,163,000$-2,533,000$-2,503,000$-2,309,000$-1,894,000$-1,738,000$-1,590,000$-1,845,000$-2,173,000$-1,856,000$-2,733,000
    EBIT$-4,268,000$-4,164,000$-2,534,000$-2,505,000$-2,309,000$-1,894,000$-1,738,000$-1,590,000$-1,846,000$-2,207,000$-1,899,000$-2,780,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHIO

    News

    Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO

    This article provides the "Price to sales forward" metric for Phio Pharmaceuticals Corp. (NASDAQ: PHIO) as listed on TradingView. It specifies that this financial data is sourced from ICE Data Services and FactSet. The core content is a financial data point for the company.

    TradingView•8/20/26•
    Neutral

    Phio Pharmaceuticals director Plott buys $17,100 in shares

    Ronald Todd Plott, a director at Phio Pharmaceuticals Corp. (NASDAQ:PHIO), recently purchased 15,000 shares for $17,100, bringing his direct ownership to 15,000 shares. This insider purchase comes as the company has also received patent allowances for its INTASYL compounds and begun commercial-scale production of its PH-762 drug substance, indicating progress in its intellectual property and production capabilities. InvestingPro notes, however, that the company is quickly burning through cash.

    Investing.com•8/20/26•
    Somewhat-Bullish

    Phio Pharmaceuticals director Plott buys $17,100 in shares

    Ronald Todd Plott, a director at Phio Pharmaceuticals Corp. (NASDAQ:PHIO), recently purchased 15,000 shares of the company's common stock for $17,100. This transaction, reported on August 20, 2026, brings his direct ownership to 15,000 shares. The company has also secured new patent allowances and initiated commercial-scale production for its PH-762 drug substance, supporting an upcoming clinical trial.

    Investing.com•8/20/26•
    Somewhat-Bullish

    Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares

    Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott purchased 15,000 shares of common stock at $1.14 per share on August 19, 2026. This transaction increased his direct holdings to 15,000 shares. The purchase, reported via a Form 4 filing, is an open-market or private transaction and not under a Rule 10b5-1 trading plan.

    Stock Titan•8/20/26•
    Bullish

    Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00

    Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman has purchased an additional 10,000 shares of the company, bringing his total holdings to 431,421 shares. This transaction at $1.06 per share reflects a strong insider sentiment, with 6 insider buys and 0 insider sells over the past year, indicating confidence in the clinical-stage biotechnology company's future despite its micro-cap status and current lack of profitability. The article highlights that such insider activity, coupled with some guru ownership, suggests a belief that the stock's current valuation does not fully reflect its long-term potential, though investors should acknowledge the inherent risks of clinical-stage biotech.

    GuruFocus•8/20/26•
    Bullish

    Frequently Asked Questions About PHIO

    Does PHIO pay dividends?
    Phio Pharmaceuticals Corp (PHIO) does not currently pay a regular dividend.
    What is PHIO's market cap?
    Phio Pharmaceuticals Corp (PHIO) has a market capitalization of $13.13M with a current stock price of $1.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In